



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, November 7, 2023

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that its licensing partner, Adium Pharma, has received the full approval for commercialization for Zepzelca® (lurbinectedin) from the Ministry of Health of Peru for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar announces the full approval of Zepzelca[®] (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Peru

Madrid, November 7th, 2023. – PharmaMar (MSE:PHM) has announced today that its licensing partner, Adium Pharma, has received the full approval for commercialization for Zepzelca[®] (lurbinectedin) from the Ministry of Health of Peru for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

This new approval of lurbinectedin is based on the monotherapy clinical data from the open-label, multi-center, single-arm clinical trial in 105 adult patients with relapsed SCLC (including patients with platinum-sensitive and platinum-resistant disease), that the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the US.

In March 2021, PharmaMar and Adium Pharma signed a licensing agreement for lurbinectedin in Latin America. The Peruvian approval of lurbinectedin has been preceded by the approval in Mexico and Ecuador.

With this approval, lurbinectedin is now authorized in 14 countries worldwide.

SCLC accounted for up to 15% of all lung cancer cases¹. Most SCLC patients are already at the advanced stage upon diagnosis, resulting in poor prognosis.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

¹ Data Monitor: Small Cell Lung Cancer (SCLC) Globocan 2020. All ages, both genders.



PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54. It also has a preclinical and clinical program in virology. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt *Ecteinascidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno – Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com